Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Oct;95(2):664–670. doi: 10.1111/j.1476-5381.1988.tb11689.x

A comparison of the differential effects of vasoactive intestinal peptide and peptide histidine isoleucine on the vascular and capsular smooth muscle of the dog spleen.

R Corder 1, P G Withrington 1
PMCID: PMC1854169  PMID: 2906563

Abstract

1. The actions of the two peptides, vasoactive intestinal peptide (VIP) and peptide histidine isoleucine (PHI) have been compared to that of isoprenaline on the smooth muscle systems of the isolated blood-perfused dog spleen. 2. Intra-arterial injections of VIP and PHI caused graded increases in splenic arterial blood flow at constant perfusion pressure indicative of splenic arterial vasodilatation. 3. VIP was significantly more potent than PHI, with their respective molar ED50 values being 9.9 +/- 3.7 and 830 +/- 141 pmol (P less than 0.002). VIP was approximately 10 and 200 times more potent than isoprenaline and PHI respectively. 4. The maximum reduction in splenic arterial vascular resistance was the same (P greater than 0.5) in response to intra-arterial VIP and PHI, although both peptide maxima were significantly less (P less than 0.05, 0.01 respectively) than that obtained with isoprenaline. 5. Small increases in spleen volume accompanied the splenic vasodilator responses to both peptides. They were probably passive in origin, secondary to splenic arterial vasodilatation. 6. The selective beta 2-adrenoceptor antagonist, ICI 118,551, did not antagonize the splenic arterial vasodilator response to VIP or PHI but markedly attenuated the effect of isoprenaline. 7. These observations indicate that VIP and PHI, when either co-released locally or present together in the systemic circulation, may exert a differential action on different components of the circulation.

Full text

PDF
664

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Corder R., Lowry P. J., Withrington P. G. The actions of the peptides, neuropeptide Y and peptide YY, on the vascular and capsular smooth muscle of the isolated, blood-perfused spleen of the dog. Br J Pharmacol. 1987 Apr;90(4):785–790. doi: 10.1111/j.1476-5381.1987.tb11232.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Della N. G., Papka R. E., Furness J. B., Costa M. Vasoactive intestinal peptide-like immunoreactivity in nerves associated with the cardiovascular system of guinea-pigs. Neuroscience. 1983 Jul;9(3):605–619. doi: 10.1016/0306-4522(83)90177-x. [DOI] [PubMed] [Google Scholar]
  3. Edvinsson L., McCulloch J. Distribution and vasomotor effects of peptide HI (PHI) in feline cerebral blood vessels in vitro and in situ. Regul Pept. 1985 Apr;10(4):345–356. doi: 10.1016/0167-0115(85)90047-3. [DOI] [PubMed] [Google Scholar]
  4. Ganz P., Sandrock A. W., Landis S. C., Leopold J., Gimbrone M. A., Jr, Alexander R. W. Vasoactive intestinal peptide: vasodilatation and cyclic AMP generation. Am J Physiol. 1986 May;250(5 Pt 2):H755–H760. doi: 10.1152/ajpheart.1986.250.5.H755. [DOI] [PubMed] [Google Scholar]
  5. Itoh N., Obata K., Yanaihara N., Okamoto H. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature. 1983 Aug 11;304(5926):547–549. doi: 10.1038/304547a0. [DOI] [PubMed] [Google Scholar]
  6. Larsson O., Dunér-Engström M., Lundberg J. M., Fredholm B. B., Anggård A. Effects of VIP, PHM and substance P on blood vessels and secretory elements of the human submandibular gland. Regul Pept. 1986 Feb;13(3-4):319–326. doi: 10.1016/0167-0115(86)90049-2. [DOI] [PubMed] [Google Scholar]
  7. Lundberg J. M., Anggård A., Pernow J., Hökfelt T. Neuropeptide Y-, substance P- and VIP-immunoreactive nerves in cat spleen in relation to autonomic vascular and volume control. Cell Tissue Res. 1985;239(1):9–18. doi: 10.1007/BF00214896. [DOI] [PubMed] [Google Scholar]
  8. Lundberg J. M., Tatemoto K. Vascular effects of the peptides PYY and PHI: comparison with APP and VIP. Eur J Pharmacol. 1982 Sep 10;83(1-2):143–146. doi: 10.1016/0014-2999(82)90300-4. [DOI] [PubMed] [Google Scholar]
  9. Mutt V., Said S. I. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. Eur J Biochem. 1974 Mar 1;42(2):581–589. doi: 10.1111/j.1432-1033.1974.tb03373.x. [DOI] [PubMed] [Google Scholar]
  10. Said S. I., Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970 Sep 18;169(3951):1217–1218. doi: 10.1126/science.169.3951.1217. [DOI] [PubMed] [Google Scholar]
  11. Said S. I., Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 1970 Feb 28;225(5235):863–864. doi: 10.1038/225863a0. [DOI] [PubMed] [Google Scholar]
  12. Tatemoto K., Mutt V. Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon--secretin family. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6603–6607. doi: 10.1073/pnas.78.11.6603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Uddman R., Alumets J., Edvinsson L., Håkanson R., Sundler F. VIP nerve fibres around peripheral blood vessels. Acta Physiol Scand. 1981 May;112(1):65–70. doi: 10.1111/j.1748-1716.1981.tb06783.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES